Navigation Links
K-V Pharmaceutical Announces Updated Makena® Performance Metrics
Date:11/8/2011

Forms 10-Q/A for the quarters ended December 31, 2010 and June 30, 2011, respectively, that will contain restated financial statements for each affected quarter. The Company expects to file all of these amended public reports within the next 30 days. Until such amended filings are made, the original filings for those periods should not be relied upon.

As a result of the need to restate prior financial statements, the Company will be unable to file its quarterly report on Form 10-Q for the quarter ended September 30, 2011 with the U.S. Securities and Exchange Commission ("SEC") by November 9, 2011, the prescribed due date.  K-V will file its fiscal 2012 second quarter 10-Q with the SEC as soon as practicable after the completion of the restatement of its prior financial statements.

Conference CallThe Company will be holding an investor conference call on Thursday, November 10, 2011 at 8:30 a.m. EST to discuss the updated Makena® performance metrics as well as other corporate developments.

Participants can listen to the conference call by dialing 866-843-0890 and providing code 9720715. To access the live webcast of the conference call, please go to the investor relations portion of the Company's website under "Conference Calls" at www.kvpharmaceutical.com.  Please log-in or dial-in at least 10 minutes prior to the start time to ensure a connection.

A replay of the call will also be available for seven days by calling 877-344-7529 and providing code 10006439. An archived version of the webcast will be accessible for 30 days at www.kvpharmaceutical.com.

About K-V Pharmaceutical CompanyK-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare.   As such, we are committed to advancing the health of women across all the stages of their lives
'/>"/>

SOURCE K-V Pharmaceutical Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. S1P1 Lead Compounds, Assets Generated by Epix Pharmaceuticals, Inc. and Amgen, Will Be Offered for Sale at a December 8, 2011 Sealed Bid Sale. Target Rationale for S1P1 Agonists Explained.
2. New Video Discusses Dust Collection Equipment for Pharmaceutical Containment
3. Critical Alerts For Barrick Gold, Molycorp, Lockheed Martin, Teva Pharmaceutical, and Tenaris Released By Seven Summits Research
4. Onyx Pharmaceuticals Announces Data Presentations Highlighting Carfilzomib at 53rd American Society of Hematology Annual Meeting
5. Anadys Pharmaceuticals Reports Third Quarter 2011 Financial Results and Highlights
6. Planet Biopharmaceuticals, Inc. Divests Assets of Allergy Control Products, Inc.
7. Ancor Acquires WellSpring Pharmaceutical Corporation
8. Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
9. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
10. Global Pharm Holdings Group, Inc. Completes Acquisition of Qingdao Likang Pharmaceutical Co., Ltd.
11. Vanda Pharmaceuticals Reports Third Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 Breckenridge Pharmaceutical, Inc. announced today ... MSN Laboratories Pvt. Ltd. ( Hyderabad, India ... several new ANDAs.  Under the terms of the agreement, ... to Breckenridge for the U.S. market, and Breckenridge will ... and MSN have agreed to develop an oral antibiotic ...
(Date:12/19/2014)...  Monarch America Inc. (OTCQB: CANK) ("Monarch America" or ... provide this review of the Company,s recent achievements and ... "Over this past year, we achieved many of our ... to say that Monarch America is in a stronger ... been," stated Eric Hagen , CEO of Monarch ...
(Date:12/19/2014)... 2014 Research and Markets ( ... "Micro Market Monitor: North American Dermatology Diagnostic ... http://photos.prnewswire.com/prnh/20130307/600769 ... which has resulted in fueling the overall demand ... purpose of these dermatology devices is to assist ...
Breaking Medicine Technology:Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3
... Feb. 17 Northwest,Biotherapeutics, Inc. (OTC Bulletin Board: ... today announced further long-term follow-up data, for the,second ... and Phase I/II clinical trials,with DCVax(R)-Brain in patients ... of brain cancer. During the update period from ...
... of eleven wounds healed in 6 weeks or lessPRINCETON, ... (OTC Bulletin Board: DSCI ), a provider of ... Dressings were the focus of a case series on ... previously failed to heal while being managed with such ...
Cached Medicine Technology:Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival 2Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival 3Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival 4Update of Long-Term Data on Brain Cancer Patients Receiving DCVax(R)-Brain Continues to Show Striking Improvements in Delay of Disease and Survival 5MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series 2MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series 3
(Date:12/20/2014)... An improving macroeconomic landscape and a growing ... Massage Services industry over the five years to ... anticipated 1.0% annualized increase in per capita disposable income ... means to afford additional massages. “While the share of ... given year has declined from 2009 to 2012, this ...
(Date:12/20/2014)... December 20, 2014 The print component ... with a distribution of approximately 160,000 copies and an ... nationally through a vast social media strategy and across ... To explore the digital version of the campaign, ... exclusive interview with the ladies of CTV’s The Social. ...
(Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... Developers of FCPX 3rd ... plugin for Final Cut Pro X entitled TranSlice Volume ... allows users to create hand drawn text animations without ... CEO of Pixel Film Studios. “TranSlice Volume 5 was ... an easy to use interface.” , TranSlice Volume 5 ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:The ladies of The Social urge Canadian women to put themselves first over the holiday season and into the new year in Mediaplanet’s “Women’s Health” campaign 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Pixel Film Studios released a new transition entitled TranSlice Volume 5 exclusively for Final Cut Pro X 2
... , CHICAGO, Aug. 14 International Components ... manufacturing portable rechargeable systems, today launched a new series ... range of electronic devices. Marketed under the Elpac Power ... the company,s rapidly expanding portfolio of high-efficiency power supplies ...
... KENILWORTH, N.J., Aug. 14 Schering-Plough Corporation (NYSE: ... Drug Administration (FDA) has approved SAPHRIS((R)) (asenapine) sublingual tablets for ... manic or mixed episodes associated with bipolar I disorder with ... as a first-line treatment and is the first psychotropic drug ...
... , , , ... OXBO) today announced that the company has received approval to begin ... of Oxycyte(R) in traumatic brain injury (TBI). Oxycyte is the Company,s ... approval from Swissmedic means that we can begin enrolling patients," said ...
... , ... Web-based admissions software for long-term care will present a technology and admissions educational session ... ... of automated Web-based admissions for long-term care providers, announced today that it will present ...
... ... 40% of women find holidays more stressful than they should be. A male,s ... is their biggest nightmare. Under 30s are the most stressed on holiday. , ... Cardiff, UK (PRWEB) August 14, 2009 ...
... raise or lower clot risk , THURSDAY, Aug. 13 ... pill influences her risk of developing blood clots of ... have long known that oral contraceptives, which contain the ... deep vein thrombosis of the leg and pulmonary embolism, ...
Cached Medicine News:Health News:Elpac Power System Extends Energy Star Portfolio with 65-Watt External Power Supply 2Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 2Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 3Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 4Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 5Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 6Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 7Health News:Video: Schering-Plough Announces FDA Approval of SAPHRIS(R) (asenapine) for Acute Treatment of Schizophrenia In Adults and Manic or Mixed Episodes of Bipolar I Disorder With or Without Psychotic Features In Adults 8Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 2Health News:Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland 3Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 3Health News:Spain Has The 'Stress' Factor, According to Confused.com 2Health News:Spain Has The 'Stress' Factor, According to Confused.com 3Health News:Some Birth Control Pills Safer Than Others 2Health News:Some Birth Control Pills Safer Than Others 3
... The Evans AFO is designed to ... disorders associated with immobility such as hip ... at the calcaneus. A comfortable Kodel lining ... patient. The anti-rotation bar is easily ...
Provides secure fracture immobilization while allowing for full range of motion at shoulder and elbow...
... MPO® by RCAI provides adjustable static stretch ... conditions such as diminished foot and ankle ... rotation. Medial/lateral straps attached to the sides ... ankle to be controlled, as needed, in ...
... features a completely padded posterior shell ... to provide passive flexion to help ... or Achilles tendonitis. Its neutral ... left or right. A foam ...
Medicine Products: